ABBOTT LABORATORI…
USUSDABBOTT LABORATORIES (XETRA:ABL) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 4. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la Empresa
- Sitio Web
- abbott.com
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede Central
- North Chicago, United States
- Consejero Delegado
- Robert Ford
- Empleados
- 73 000
- Fundada
- 1888
- Cotiza Desde
- 20.12.2007 (XETRA:ABL)
- Acciones en Circulación
- 1.73 mil M a 2026-06-30
- Capital Flotante
- 1.72 mil M
- Capitalización Bursátil
- 169.83 mil M USD
- Insiders
- 0.49%
- Inversores Institucionales
- 81.79%
- Industria (SIC)
- Pharmaceutical Preparations
- Forma Jurídica
- AZUK
- ISIN
- US0028241000
- LEI
- HQD377W2YR662HK5JX27
- P/E
- 33.4
- Ratio de Reparto
- 66.7%
- FCF
- 7.38 mil M USD
- Pagos / FCF
- 57%
- Deuda
- 34.0 mil M USD3.7 a. de FCF
- Racha de Dividendos
- 43 a.
- Beneficios, FCF y dividendos pagados — para los 12 meses hasta 31.03.2026 (el último informe de la compañía).
- NAV
Descripción
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Bolsas y Tickers
Dividendos
ABBOTT LABORATORIES (ABL) paga dividendos trimestralmente. Por año (12 meses hasta e incluyendo el último pago anunciado): 1.6798 EUR por acción (pagos: 3). Eso representa aproximadamente el 1.89% del precio actual de la acción. Según el historial de pagos, se espera la próxima fecha ex-dividendo alrededor de 13.01.2027. Historial de dividendos ininterrumpido: 43 años.
| Fecha Ex | Pago | Importe | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-07-15 | — | 0.5599 EUR | 0.7/2.8 % | trimestral | XETRA:ABL |
| 2026-04-15 | — | 0.5599 EUR | 0.6/2.5 % | trimestral | XETRA:ABL |
| 2026-01-15 | — | 0.5599 EUR | 0.5/2.0 % | trimestral | XETRA:ABL |
| 2025-10-15 | — | 0.5244 EUR | 0.5/1.8 % | trimestral | XETRA:ABL |
| 2025-07-15 | — | 0.5244 EUR | 0.5/1.8 % | trimestral | XETRA:ABL |
| 2025-04-15 | — | 0.5244 EUR | 0.5/1.8 % | trimestral | XETRA:ABL |
| 2025-01-15 | — | 0.5244 EUR | 0.5/1.8 % | trimestral | XETRA:ABL |
| 2024-10-15 | — | 0.4888 EUR | 0.5/1.8 % | trimestral | XETRA:ABL |
| 2024-07-15 | — | 0.4888 EUR | 0.5/2.0 % | trimestral | XETRA:ABL |
| 2024-04-12 | — | 0.4888 EUR | 0.5/1.8 % | trimestral | XETRA:ABL |
| 2024-01-11 | — | 0.4888 EUR | 0.5/1.8 % | trimestral | XETRA:ABL |
| 2023-10-12 | — | 0.4533 EUR | 0.5/2.0 % | trimestral | XETRA:ABL |
| 2023-07-13 | — | 0.4533 EUR | 0.5/1.8 % | trimestral | XETRA:ABL |
| 2023-04-13 | — | 0.4533 EUR | 0.5/1.9 % | trimestral | XETRA:ABL |
| 2023-01-12 | — | 0.4533 EUR | 0.4/1.6 % | trimestral | XETRA:ABL |
| 2022-10-13 | — | 0.4177 EUR | 0.4/1.6 % | trimestral | XETRA:ABL |
| 2022-07-14 | — | 0.4177 EUR | 0.4/1.2 % | trimestral | XETRA:ABL |
| 2022-04-13 | — | 0.4177 EUR | 0.4/0.8 % | trimestral | XETRA:ABL |
| 2022-01-13 | — | 0.4177 EUR | 0.4/0.4 % | trimestral | XETRA:ABL |
Noticias de Esta Semana
Comunicados de prensa desde la página web para inversores de la empresa, actualizados diariamente. Los enlaces conducen a la página web de la empresa. Los titulares están en el idioma original, como en la página web de la empresa.
| 13.10.2026 | Newsroom | Top Stories |
| 12.10.2026 | Newsroom | Top Stories |
Principales Accionistas
| Titular | Participación | Acciones | Fecha del Informe |
|---|---|---|---|
| BlackRock | 8.82% | 152.56 M | 2026-06-30 |
| Vanguard Capital Managem… | 6.57% | 113.75 M | 2026-06-30 |
| State Street Corporation | 4.68% | 80.93 M | 2026-06-30 |
| Charles Schwab Investmen… | 3.45% | 59.67 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.2% | 55.3 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.83% | 49.02 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.61% | 45.14 M | 2026-06-30 |
| Geode Capital Management… | 2.27% | 39.22 M | 2026-06-30 |
| Capital Research Global… | 2.13% | 36.91 M | 2026-06-30 |
| Capital International In… | 2% | 34.65 M | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 1.9% | 32.82 M | 2026-05-31 |
| Morgan Stanley | 1.54% | 26.61 M | 2026-06-30 |
| NORGES BANK | 1.35% | 23.35 M | 2026-06-30 |
| iShares Trust-iShares Co… | 1.34% | 23.2 M | 2026-08-31 |
| Fidelity Concord Street… | 1.3% | 22.52 M | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.23% | 21.31 M | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.01% | 17.53 M | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 0.96% | 16.58 M | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 12.52 M | 2026-08-31 |
| Investment Co of America | 0.6% | 10.33 M | 2026-06-30 |
| STARKS DANIEL J (Directo… | ≈0.39% | 6.75 M | 2026-04-27 |
| FORD ROBERT B. (Chief Ex… | ≈0.03% | 522 664 | 2026-08-25 |
| ALLEN HUBERT L. (Officer… | ≈0.01% | 200 281 | 2025-02-25 |
| SALVADORI DANIEL GESUA S… | ≈0.01% | 146 377 | 2026-03-02 |
| CONROY KEVIN T (Director… | ≈0.01% | 133 737 | 2026-04-24 |
| MORELAND MARY K (Officer… | ≈0.01% | 116 136 | 2026-03-02 |
| EARNHARDT LISA D (Office… | ≈0.01% | 98 984 | 2026-02-24 |
| SCOGGINS CHRISTOPHER J (… | ≈0% | 82 123 | 2026-02-24 |
| WAINER ANDREA F (Officer… | ≈0% | 74 381 | 2025-03-03 |
| The Vanguard Group | — | — | — |
| BOUDREAU PHILIP P (Chief… | — | — | 2026-04-23 |
